{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:23:52Z","timestamp":1782379432830,"version":"3.54.5"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ejca.2022.09.036","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T07:08:48Z","timestamp":1665731328000},"page":"120-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors"],"prefix":"10.1016","volume":"177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8738-5913","authenticated-orcid":false,"given":"Andrew DJ.","family":"Pearson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Fangusaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2059-4814","authenticated-orcid":false,"given":"Caroline","family":"Hutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Reaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5403-3989","authenticated-orcid":false,"given":"Mark","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratiti","family":"Bandopadhayay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sama","family":"Ahsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6890-2444","authenticated-orcid":false,"given":"Elly","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7749-8423","authenticated-orcid":false,"given":"Teresa","family":"de Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3408-3839","authenticated-orcid":false,"given":"Michael","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9998-5326","authenticated-orcid":false,"given":"Elizabeth","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5316-6440","authenticated-orcid":false,"given":"Julia Glade","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Hargrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3602-1375","authenticated-orcid":false,"given":"Doug","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3223-1466","authenticated-orcid":false,"given":"Brent","family":"Kreider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2077-2828","authenticated-orcid":false,"given":"Abraham J.","family":"Langseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Lesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franca","family":"Ligas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Marotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6537-2118","authenticated-orcid":false,"given":"Lynley V.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kahina","family":"Nasri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Norga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2935-0058","authenticated-orcid":false,"given":"Karsten","family":"Nysom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Pappo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Rossato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6539-2741","authenticated-orcid":false,"given":"Nicole","family":"Scobie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-9876","authenticated-orcid":false,"given":"Malcolm","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7032-4623","authenticated-orcid":false,"given":"Elliot","family":"Stieglitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Weigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Viana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Karres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Vassal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.09.036_bib1","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3390\/cancers11101618","article-title":"A comprehensive review on MAPK: a promising therapeutic target in cancer","volume":"11","author":"Braicu","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2022.09.036_bib2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature25480","article-title":"The landscape of genomic alterations across childhood cancers","volume":"555","author":"Gr\u00f6bner","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2022.09.036_bib3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature25795","article-title":"Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours","volume":"555","author":"Ma","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2022.09.036_bib4","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1158\/0008-5472.CAN-20-0916","article-title":"The emerging role of Ras pathway signaling in pediatric cancer","volume":"80","author":"Ney","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2022.09.036_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2022.09.036_bib6","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-2138","article-title":"Molecular pathways and mechanisms of BRAF in cancer therapy","author":"Poulikakos","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.09.036_bib7","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS G12C inhibition with Sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.09.036_bib8","article-title":"The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy","volume":"6","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2022.09.036_bib9","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"1Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.09.036_bib10","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.09.036_bib11","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMx200013","article-title":"Selumetinib in children with inoperable plexiform neurofibromas (Erratum)","volume":"383","author":"Gross","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.09.036_bib12","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1158\/1078-0432.CCR-20-5032","article-title":"FDA approval summary: selumetinib for plexiform neurofibroma","volume":"27","author":"Casey","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.09.036_bib13","doi-asserted-by":"crossref","first-page":"7303","DOI":"10.1158\/1078-0432.CCR-19-2177","article-title":"Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation-positive relapsed or refractory low-grade glioma: results from a phase I\/IIa study","volume":"25","author":"Hargrave","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.09.036_bib14","doi-asserted-by":"crossref","first-page":"7294","DOI":"10.1158\/1078-0432.CCR-17-3572","article-title":"A phase I and pharmacokinetic study of oral dabrafenib in children and adolescent patients with recurrent or refractory BRAF V600 mutation-positive solid tumors","volume":"25","author":"Kieran","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"Supplement 2","key":"10.1016\/j.ejca.2022.09.036_bib15","doi-asserted-by":"crossref","first-page":"ii46","DOI":"10.1093\/neuonc\/noaa215.186","article-title":"CTNI-19. Phase I trial of Day101 in pediatric patients with radiographically recurrent or progressive low grade glioma (LGG)","volume":"22","author":"Wright","year":"2020","journal-title":"Neuro Oncol"},{"issue":"suppl","key":"10.1016\/j.ejca.2022.09.036_bib16","article-title":"Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in BRAF V600\u2013mutant pediatric low-grade glioma (pLGG)","volume":"36","author":"Bouffet E Hansford","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.ejca.2022.09.036_bib17","article-title":"Dabrafenib in pediatric patients with BRAF V600\u2013positive high-grade glioma (HGG)","volume":"36","author":"Hargrave","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.09.036_bib18","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/neuonc\/noab247","article-title":"Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review","volume":"24","author":"Andrews","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2022.09.036_bib19","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.19.00456","article-title":"Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study","volume":"37","author":"Donadieu","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.09.036_bib20","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1002\/cncr.32197","article-title":"Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations","volume":"125","author":"Juratli","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.09.036_bib21","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.09.036_bib22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11060-020-03640-3","article-title":"Response to trametinib treatment in progressive pediatric low-grade glioma patients","volume":"149","author":"Selt","year":"2020","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.ejca.2022.09.036_bib23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","volume":"567","author":"Diamond","year":"2019","journal-title":"Nature"},{"issue":"Supplement 1","key":"10.1016\/j.ejca.2022.09.036_bib24","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2021-144850","article-title":"MEK inhibition demonstrates activity in relapsed, refractory patients with juvenile myelomonocytic leukemia: results from COG study ADVL1521","volume":"138","author":"Stieglitz","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.09.036_bib25","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ejca.2014.10.029","article-title":"Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer","volume":"51","author":"Vassal","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.09.036_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejca.2022.01.033","article-title":"Accelerate - five years accelerating cancer drug development for children and adolescents","volume":"166","author":"Pearson","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.09.036_bib27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2019.01.013","article-title":"ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children","volume":"110","author":"Pearson","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.09.036_bib28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2019.12.029","article-title":"ACCELERATE and European medicines agency paediatric strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients","volume":"127","author":"Pearson","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.09.036_bib29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2020.04.038","article-title":"Paediatric strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents","volume":"136","author":"Pearson","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.09.036_bib30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejca.2020.08.014","article-title":"Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration","volume":"139","author":"Pearson","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.09.036_bib31","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejca.2021.08.022","article-title":"Second paediatric strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies ACCELERATE in collaboration with the European medicines agency with the participation of the Food and drug administration","volume":"157","author":"Pearson","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.09.036_bib32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2021.10.016","article-title":"Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration","volume":"160","author":"Pearson","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.09.036_bib33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejca.2022.06.008","article-title":"Paediatric strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas","volume":"173","author":"Pearson","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.09.036_bib34","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ng.3400","article-title":"The genomic landscape of juvenile myelomonocytic leukemia","volume":"47","author":"Stieglitz","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2022.09.036_bib35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/ng.3500","article-title":"MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism","volume":"48","author":"Bandopadhayay","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2022.09.036_bib36","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ng.2611","article-title":"Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas","volume":"45","author":"Zhang","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2022.09.036_bib37","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1158\/0008-5472.CAN-08-2097","article-title":"Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas","volume":"68","author":"Jones","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2022.09.036_bib38","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev-genet-120417-031642","article-title":"The Power of human cancer genetics as Revealed by low-grade gliomas","volume":"53","author":"Jones","year":"2019","journal-title":"Annu Rev Genet"},{"key":"10.1016\/j.ejca.2022.09.036_bib39","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated molecular Meta-analysis of 1,000 pediatric high-grade and Diffuse Intrinsic Pontine glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2022.09.036_bib40","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1158\/2159-8290.CD-20-0930","article-title":"DIPG Harbors alterations targetable by MEK inhibitors, with Acquired resistance mechanisms Overcome by Combinatorial inhibition","volume":"12","author":"Izquierdo","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2022.09.036_bib41","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2014-05-577825","article-title":"Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis","volume":"124","author":"Chakraborty","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.09.036_bib42","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-13-0639","article-title":"Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors","volume":"4","author":"Shern","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2022.09.036_bib43","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/ng.3333","article-title":"Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations","volume":"47","author":"Eleveld","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2022.09.036_bib44","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1002\/ONCO.13519","article-title":"Targetable BRAF and RAF1 alterations in advanced pediatric cancers","volume":"26","author":"Rankin","year":"2021","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2022.09.036_bib45","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation","volume":"23","author":"Legius","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.ejca.2022.09.036_bib46","doi-asserted-by":"crossref","first-page":"14087","DOI":"10.1523\/JNEUROSCI.3242-12.2012","article-title":"Neurofibromatosis type 1: modeling CNS dysfunction","volume":"32","author":"Gutmann","year":"2012","journal-title":"J Neurosci"},{"key":"10.1016\/j.ejca.2022.09.036_bib47","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","article-title":"Neurofibromatosis type 1: a multidisciplinary approach to care","volume":"13","author":"Hirbe","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ejca.2022.09.036_bib48","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/ng.2682","article-title":"Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma","volume":"45","author":"Jones","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2022.09.036_bib49","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/s41591-021-01304-x","article-title":"BRAF V600E-induced senescence drives Langerhans cell histiocytosis pathophysiology","volume":"27","author":"Bigenwald","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2022.09.036_bib50","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/neuonc\/noy188","article-title":"Old meet new-the path to combination treatments in pediatric low-grade gliomas","volume":"21","author":"Clymer","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2022.09.036_bib51","first-page":"774","article-title":"A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas","volume":"19","author":"Sun","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2022.09.036_bib52","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/neuonc\/nou059","article-title":"Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2022.09.036_bib53","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.1016\/j.febslet.2006.08.025","article-title":"Functions of the MAPK family in vertebrate-development","volume":"580","author":"Krens","year":"2006","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ejca.2022.09.036_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004193","article-title":"Mitogen-activated protein kinase (MAPK) pathway regulates branching by remodeling epithelial cell adhesion","volume":"10","author":"Ihermann-Hella","year":"2014","journal-title":"PLoS Genet"},{"key":"10.1016\/j.ejca.2022.09.036_bib55","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.neuron.2012.08.031","article-title":"MEK is a key regulator of gliogenesis in the developing brain","volume":"75","author":"Li","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.ejca.2022.09.036_bib56","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.devcel.2007.03.009","article-title":"Mek1\/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia","volume":"12","author":"Scholl","year":"2007","journal-title":"Dev Cell"},{"key":"10.1016\/j.ejca.2022.09.036_bib57","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/children8111075","article-title":"Pediatric and adult low-grade gliomas: where do the differences Lie?","volume":"8","author":"Greuter","year":"2021","journal-title":"Children"},{"key":"10.1016\/j.ejca.2022.09.036_bib58","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejca.2017.04.019","article-title":"A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (\u226416 years) low grade glioma - a final report","volume":"81","author":"Gnekow","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.09.036_bib59","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1002\/ijc.33170","article-title":"Loss of efficacy of subsequent nonsurgical therapy after primary treatment failure in pediatric low-grade glioma patients-Report from the German SIOP-LGG 2004 cohort","volume":"147","author":"Kandels","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2022.09.036_bib60","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2022.09.036_bib61","unstructured":"https:\/\/www.who.int\/docs\/default-source\/documents\/health-topics\/cancer\/who-childhood-cancer-overview-booklet.pdf. (Accessed 8 July 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib62","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/neuonc\/noab047","article-title":"A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study","volume":"23","author":"Fangusaro","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2022.09.036_bib63","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1078-0432.CCR-18-1965","article-title":"The senescence-associated secretory phenotype Mediates oncogene-induced senescence in pediatric pilocytic astrocytoma","volume":"25","author":"Buhl","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.09.036_bib64","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-11-0127","article-title":"Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas","volume":"17","author":"Jacob","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.09.036_bib65","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1038\/s41467-019-11493-2","article-title":"Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells","volume":"10","author":"Reitman","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2022.09.036_bib66","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/neuonc\/nox141","article-title":"Pediatric low-grade gliomas: next biologically driven steps","volume":"20","author":"Jones","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2022.09.036_bib67","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00401-015-1405-4","article-title":"Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers","volume":"129","author":"Korshunov","year":"2015","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ejca.2022.09.036_bib68","unstructured":"Phase II Pediatric Study with Dabrafenib in Combination with Trametinib in Patients with HGG and LGG - https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02684058. (Accessed 8 July 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib69","unstructured":"Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03919071. (Accessed 6 September 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib70","unstructured":"Study of Binimetinib with Encorafenib in Adults with Recurrent BRAF V600-Mutated HGG (BRAF). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03973918. (Accessed 6 September 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib71","unstructured":"A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients with Recurrent LGG or HGG with a BRAF Aberration. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04201457. (Accessed 6 September 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib72","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noac096","article-title":"Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma","author":"Rosenberg","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2022.09.036_bib73","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1158\/1078-0432.CCR-21-2660","article-title":"Deconvoluting mechanisms of Acquired resistance to RAF inhibitors in BRAF V600E-mutant human glioma","volume":"27","author":"Schreck","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.09.036_bib74","first-page":"55","article-title":"Natural history and disease burden of neurofibromatosis type 1 with plexiform neurofibromas: a systematic Literature review","volume":"12","author":"Copley-Merriman","year":"2021","journal-title":"Adolesc Health Med Ther"},{"key":"10.1016\/j.ejca.2022.09.036_bib75","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.20.02220","article-title":"NF106: a neurofibromatosis clinical trials Consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas","volume":"39","author":"Weiss","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.09.036_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100223","article-title":"Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review","volume":"6","author":"Solares","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2022.09.036_bib77","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJMra1607548","article-title":"Langerhans-cell histiocytosis","volume":"379","author":"Allen","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.09.036_bib78","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1182\/blood-2012-09-455774","article-title":"Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis","volume":"121","author":"Gadner","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.09.036_bib79","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jpeds.2008.05.002","article-title":"International Study Group. Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry","volume":"153","author":"Minkov","year":"2008","journal-title":"J Pediatr"},{"key":"10.1016\/j.ejca.2022.09.036_bib80","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26784","article-title":"Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: current views and new vistas","volume":"65","author":"Yeh","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ejca.2022.09.036_bib81","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","article-title":"Recurrent BRAF mutations in Langerhans cell histiocytosis","volume":"116","author":"Badalian-Very","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.09.036_bib82","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2018-10-878363","article-title":"NACHO-LIBRE Study Group. Clinical responses and persistent BRAF V600E + blood cells in children with LCH treated with MAPK pathway inhibition","volume":"133","author":"Eckstein","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.09.036_bib83","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/2159-8290.CD-14-0742","article-title":"Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders","volume":"5","author":"Hyman","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2022.09.036_bib84","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/bloodadvances.2021005442","article-title":"Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis","volume":"6","author":"Eder","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2022.09.036_bib85","doi-asserted-by":"crossref","unstructured":"Whitlock JA, Geoerger B, Roughton M, Choi J, Osterloh L, Russo M et\u00a0al. Dabrafenib, alone or in combination with trametinib, in Pediatric patients with BRAF V600 mutation-positive Langerhans cell histiocytosis https:\/\/ashpublications.org\/blood\/article\/138\/Supplement201\/3618\/479771\/ (Accessed 6 September 2022).","DOI":"10.1182\/blood-2021-147377"},{"key":"10.1016\/j.ejca.2022.09.036_bib86","unstructured":"Trametinib in Treating Patients with Relapsed or Refractory Juvenile Myelomonocytic Leukemia. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03190915. (Accessed 6 September 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib87","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.3324\/haematol.2020.259226","article-title":"Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations","volume":"106","author":"Anti\u0107","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2022.09.036_bib88","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2014-04-531871","article-title":"Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition","volume":"124","author":"Irving","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.09.036_bib89","unstructured":"International Trial of Selumetinib in Combination with Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia (SeluDex). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03705507. (Accessed 6 September 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib90","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-059872","volume":"12","author":"Menne","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejca.2022.09.036_bib91","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41467-018-04180-1","article-title":"De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia","volume":"9","author":"Hyrenius-Wittsten","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2022.09.036_bib92","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/paediatric-investigation-plans\/emea-000978-pip01-10-m01. (Accessed 6 September 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib93","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1200\/JCO.20.02152","article-title":"Accelerating the global development of pediatric cancer drugs: a call to coordinate the submissions of pediatric investigation plans and pediatric study plans to the European medicines agency and US Food and drug administration","volume":"38","author":"Reaman","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.09.036_bib94","unstructured":"Common Commentary - EMA\/FDA Common issues requested for discussion by the respective agency (EMA\/PDCO and FDA) concerning paediatric oncology development plans (Paediatric Investigation Plans [PIPs] and initial Pediatric Study Plans [iPSPs]). https:\/\/www.fda.gov\/media\/147197. (Accessed 6 September 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib95","unstructured":"Common Commentary - EMA\/FDA Common issues requested for discussion by the respective agency (EMA\/PDCO and FDA) concerning paediatric oncology development plans (Paediatric Investigation Plans [PIPs] and initial Pediatric Study Plans [iPSPs]). https:\/\/www.ema.europa.eu\/en\/documents\/other\/common-commentary-ema\/fda-common-issues-requested-discussion-respective-agency-ema\/pdco-fda-concerning-paediatric-oncology-development-plans-paediatric-investigation-plans-pips_en.pdf. (Accessed 6 September 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib96","article-title":"Common Commentary on paediatric oncology drug development","author":"Karres","year":"2021","journal-title":"Ther Innov Regul Sci"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2022.09.036_bib97","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.10537","article-title":"Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN)","volume":"36","author":"Geoerger","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.09.036_bib98","article-title":"MEK inhibitors for neurofibromatosis type 1 Manifestations: clinical evidence and consensus","author":"de Blank","year":"2022","journal-title":"Neuro Onol"},{"issue":"Supplement_3","key":"10.1016\/j.ejca.2022.09.036_bib99","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaa222.430","article-title":"LGG-52Binimetinib in children with progressive or recurrent low-grade glioma not associated with neurofibromatosis type 1: initial results from a multi-institutional phase ii study","volume":"22","author":"Robison","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2022.09.036_bib100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jnci\/djab087","article-title":"Patient-reported outcomes in pediatric cancer Registration trials: a US Food and drug administration perspective","volume":"114","author":"Murugappan","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2022.09.036_bib101","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-045226","article-title":"MyPal-Child study protocol: an observational prospective clinical feasibility study of the MyPal ePRO-based early palliative care digital system in paediatric oncology patients","volume":"11","author":"Meyerheim","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejca.2022.09.036_bib102","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29047","article-title":"ACCELERATE Long-Term Follow-Up Working Group. A global approach to long-term follow-up of targeted and immune-based therapy in childhood and adolescence","volume":"68","author":"Kieran","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ejca.2022.09.036_bib103","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1200\/JCO.21.02840","article-title":"Phase II study of selumetinib in children and young adults with tumors harboring activating mitogen-activated protein kinase pathway genetic alterations: arm E of the NCI-COG pediatric MATCH trial","volume":"40","author":"Eckstein","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.09.036_bib104","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial","volume":"23","author":"Wen","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.09.036_bib105","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/ajmg.a.61485","article-title":"Advancing RAS\/RASopathy therapies: an NCI-sponsored intramural and extramural collaboration for the study of RASopathies","volume":"182","author":"Gross","year":"2020","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.ejca.2022.09.036_bib106","unstructured":"A Study of the Drugs Selumetinib Versus Carboplatin\/Vincristine in Patients with Neurofibromatosis and Low-Grade Glioma - https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03871257. (Accessed 6 September 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib107","unstructured":"A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients with Low-Grade Glioma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04166409. (Accessed 6 September 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib108","unstructured":"Pediatric Low Grade Glioma \u2013 MEKinhibitor TRIal vs Chemotherapy (PLGG - MEKTRIC). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05180825 (Accessed 6 September 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib109","unstructured":"A Study to Evaluate DAY101 in Pediatric and Young Adult Patients with Relapsed or Progressive Low-Grade Glioma (FIREFLY-1). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04775485. (Accessed 6 September 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib110","unstructured":"A Study to Compare Treatment with the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma - https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04576117. (Accessed 6 September 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib111","unstructured":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) - https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03155620. (Accessed 6 September 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib112","unstructured":"Phase I\/II Study of MEK162 for Children With Ras\/Raf Pathway Activated Tumors. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02285439. (Accessed 6 September 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib113","unstructured":"SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults with Low-Grade Glioma- https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04923126. (Accessed 6 September 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib114","unstructured":"Trametinib and Everolimus for the Treatment of Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas (PNOC021) - https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04485559. (Accessed 6 September 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib115","unstructured":"DAY101 in Gliomas and Other Tumors. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03429803. (Accessed 6 September 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib116","unstructured":"Selumetinib in Treating Young Patients with Recurrent or Refractory Low Grade Glioma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01089101. (Accessed 6 September 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib117","unstructured":"Sorafenib in Children and Young Adults with Recurrent or Progressive Low-Grade Astrocytomas. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01338857. (Accessed 6 September 2022)."},{"key":"10.1016\/j.ejca.2022.09.036_bib118","unstructured":"Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Subjects with Cancers Harboring V600 Mutations. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02124772. (Accessed 6 September 2022)."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922007766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922007766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:38:40Z","timestamp":1760733520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922007766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":118,"alternative-id":["S0959804922007766"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.09.036","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.09.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Merck Sharp & Dohme LLC., a subsidiary Merck & Co., Inc., Rahway, NJ, USA and The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}